Earnings summaries and quarterly performance for Edesa Biotech.
Executive leadership at Edesa Biotech.
Board of directors at Edesa Biotech.
Research analysts who have asked questions during Edesa Biotech earnings calls.
Recent press releases and 8-K filings for EDSA.
Edesa Biotech Reports Fiscal Year 2025 Results and Clinical Trial Updates
EDSA
Earnings
New Projects/Investments
- Edesa Biotech reported a net loss of $7.2 million, or $1.27 per common share, for the fiscal year ended September 30, 2025, with total operating expenses increasing to $7.9 million.
- The company ended the fiscal year with $10.8 million in cash and cash equivalents and $10.4 million in working capital as of September 30, 2025.
- A Phase 3 study of its respiratory drug candidate, paridiprubart (EB05), met primary and secondary endpoints with statistical significance, and Edesa is now exploring development and commercialization partnerships for the drug.
- Edesa also initiated manufacturing activities for a Phase 2 study of its dermatology drug candidate, EB06, for vitiligo, with patient recruitment anticipated by midyear 2026.
Dec 12, 2025, 9:25 PM
Edesa Biotech Reports Fiscal Year 2025 Results
EDSA
Earnings
New Projects/Investments
- Edesa Biotech reported a net loss of $7.2 million, or $1.27 per common share, for the fiscal year ended September 30, 2025, compared to a net loss of $6.2 million, or $1.93 per common share, for the prior year. Total operating expenses increased to $7.9 million for FY 2025, up from $7.0 million in the prior year, primarily due to increased research and development activities.
- The company ended the fiscal year with $10.8 million in cash and cash equivalents and $10.4 million in working capital as of September 30, 2025, and subsequently raised an additional $3.4 million in net proceeds from an at-the-market offering.
- In its clinical pipeline, Edesa initiated manufacturing for a Phase 2 study of its dermatology drug candidate EB06 for vitiligo, with recruitment anticipated by mid-2026, and reported that a Phase 3 study of its respiratory therapeutic paridiprubart (EB05) met primary and secondary endpoints. The company is now exploring development and commercialization partnerships for paridiprubart.
Dec 12, 2025, 9:20 PM
Edesa Biotech Announces Positive Phase 3 Study Results for Paridiprubart
EDSA
New Projects/Investments
- Edesa Biotech, Inc. announced positive results from a Phase 3 study evaluating its drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS).
- The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful benefit with a 25% relative reduction in the risk of death at 28 days for patients treated with paridiprubart plus standard of care compared to placebo (39% vs. 52% mortality, p<0.001).
- A durable survival benefit was also demonstrated at 60 days, showing a 22% relative risk reduction in mortality (46% vs. 59% mortality, p=0.003).
- Patients receiving paridiprubart plus standard of care also demonstrated a 41% higher relative rate of clinical improvement at Day 28, indicating they no longer required invasive mechanical ventilation and/or organ support.
- The safety population of over 275 subjects indicated that EB05 was generally well-tolerated.
Oct 28, 2025, 11:45 AM
Quarterly earnings call transcripts for Edesa Biotech.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more